Agenus (AGEN) Income from Non-Controlling Interests (2013 - 2026)
Agenus' (AGEN) quarterly Income from Non-Controlling Interests came in at -$20000.0 in Q1 2026, up 98.19% year-on-year from -$10091.4 in Q1 2025, and up 41.18% quarter-over-quarter from -$34000.0 in Q4 2025.
Agenus (AGEN) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Agenus' Income from Non-Controlling Interests history runs 11 years deep, the most recent figure standing at -$20000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 98.19% year-over-year to -$20000.0 in Q1 2026; TTM through Mar 2026 was -$2.1 million, a 53.99% increase from a year earlier, with the FY2025 full-year figure at -$3.2 million, up 36.79% from the prior year.
- Income from Non-Controlling Interests advanced to -$20000.0 in Q1 2026 per AGEN's latest filing, from -$34000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$3000.0 in Q3 2025 and bottomed at -$4.4 million in Q2 2023.
- The 5-year median for Income from Non-Controlling Interests is -$2.1 million (2025), against an average of -$1.8 million.
- Across the five-year window, Income from Non-Controlling Interests tumbled 299.57% in 2022 and surged 99.64% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$3.0 million in 2022, then grew by 23.83% to -$2.3 million in 2023, then soared by 58.68% to -$947000.0 in 2024, then soared by 96.41% to -$34000.0 in 2025, then jumped by 41.18% to -$20000.0 in 2026.
- Per Business Quant, the three latest AGEN Income from Non-Controlling Interests figures stand at -$20000.0 (Q1 2026), -$34000.0 (Q4 2025), and -$3000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Agenus | 222.90 Mn | 222.90 Mn | 33.74 Mn | -20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -34,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -2.06 Mn |
| Mar 31, 2025 | -1.10 Mn |
| Dec 31, 2024 | -947,000.00 |
| Sep 30, 2024 | -828,000.00 |
| Jun 30, 2024 | -1.72 Mn |
| Mar 31, 2024 | -1.57 Mn |
| Dec 31, 2023 | -2.29 Mn |
| Sep 30, 2023 | -2.33 Mn |
| Jun 30, 2023 | -4.41 Mn |
| Mar 31, 2023 | -2.64 Mn |
| Dec 31, 2022 | -3.01 Mn |
| Sep 30, 2022 | -2.49 Mn |
| Jun 30, 2022 | -2.80 Mn |
| Mar 31, 2022 | -2.28 Mn |
| Dec 31, 2021 | -2.10 Mn |
| Sep 30, 2021 | -1.28 Mn |
| Jun 30, 2021 | -701,000.00 |